keyword
MENU ▼
Read by QxMD icon Read
search

Muc1 breast cancer

keyword
https://www.readbyqxmd.com/read/28211299/comparison-of-biodistribution-profile-of-monoclonal-antibodies-nanoparticles-and-aptamers-in-rats-with-breast-cancer
#1
COMPARATIVE STUDY
Cristal Cerqueira-Coutinho, Sotiris Missailidis, Jéssica Alessandra-Perini, Daniel Escorsim Machado, Jamila Alessandra Perini, Ralph Santos-Oliveira
The use of monoclonal antibodies and aptamers is growing every single day, as the use of nanoparticle systems. Although most of the products are under investigation, there are a few commercialized products available at the market, for human consume. In this study, we have compared three formulations (aptamer anti-MUC1, monoclonal antibody - Trastuzumab and monoclonal antibodies nanoparticles - PLA/PVA/MMT trastuzumab) to identify their profile as also to understand their behavior into an alive biological system...
May 2017: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/28171795/multifunctional-silver-nanocluster-hybrid-oligonucleotide-vehicle-for-cell-imaging-and-microrna-targeted-gene-silencing
#2
Hau-Yun Chen, Karunya Albert, Cheng-Che Wen, Pei-Ying Hsieh, Sih-Yu Chen, Nei-Chung Huang, Shen-Chuan Lo, Jen-Kun Chen, Hsin-Yun Hsu
Novel therapeutics is urgently needed to prevent cancer-related deaths. MicroRNAs that act as tumor suppressors have been recognized as a next-generation tumor therapy, and the restoration of tumor-suppressive microRNAs using microRNA replacements or mimics may be a less toxic, more effective strategy due to fewer off-target effects. Here, we designed the novel multifunctional oligonucleotide nanocarrier complex composed of a tumor-targeting aptamer sequence specific to mucin 1 (MUC1), poly-cytosine region for fluorescent silver nanocluster (AgNC) synthesis, and complimentary sequence for microRNA miR-34a loading...
April 1, 2017: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/28053523/anti-muc1-nano-aptamers-for-triple-negative-breast-cancer-imaging-by-single-photon-emission-computed-tomography-in-inducted-animals-initial-considerations
#3
Fagner Santos do Carmo, Eduardo Ricci-Junior, Cristal Cerqueira-Coutinho, Marta de Souza Albernaz, Emerson Soares Bernardes, Sotiris Missailidis, Ralph Santos-Oliveira
The early and specific detection of tumors remains a barrier in oncology, especially in cases such as the triple-negative breast cancer (TNBC). To address this gap, aptamers have found an important application in the recognition of tumor biomarkers such as mucin 1 (MUC1). However, there are still some difficulties in the use of aptamer, as their rapid biological clearance makes their use as drugs limited. In this study, the anti-MUC1 aptamer was used as a drug delivery system (DDS) for a radioactive polymeric nanoparticle (NP) in the imaging of TNBCs...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/27974697/surrogate-in-vitro-activation-of-innate-immunity-synergizes-with-interleukin-7-to-unleash-rapid-antigen-driven-outgrowth-of-cd4-and-cd8-human-peripheral-blood-t-cells-naturally-recognizing-muc1-her2-neu-and-other-tumor-associated-antigens
#4
Latha B Pathangey, Dustin B McCurry, Sandra J Gendler, Ana L Dominguez, Jessica E Gorman, Girish Pathangey, Laurie A Mihalik, Yushe Dang, Mary L Disis, Peter A Cohen
Effective adoptive immunotherapy has proved elusive for many types of human cancer, often due to difficulties achieving robust expansion of natural tumor-specific T-cells from peripheral blood. We hypothesized that antigen-driven T-cell expansion might best be triggered in vitro by acute activation of innate immunity to mimic a life-threatening infection. Unfractionated peripheral blood mononuclear cells (PBMC) were subjected to a two-step culture, first synchronizing their exposure to exogenous antigens with aggressive surrogate activation of innate immunity, followed by γ-chain cytokine-modulated T-cell hyperexpansion...
December 11, 2016: Oncotarget
https://www.readbyqxmd.com/read/27893710/muc1-c-activates-bmi1-in-human-cancer-cells
#5
M Hiraki, T Maeda, A Bouillez, M Alam, A Tagde, K Hinohara, Y Suzuki, T Markert, M Miyo, K Komura, R Ahmad, H Rajabi, D Kufe
B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1) is a component of the polycomb repressive complex 1 (PRC1) complex that is overexpressed in breast and other cancers, and promotes self-renewal of cancer stem-like cells. The oncogenic mucin 1 (MUC1) C-terminal (MUC1-C) subunit is similarly overexpressed in human carcinoma cells and has been linked to their self-renewal. There is no known relationship between MUC1-C and BMI1 in cancer. The present studies demonstrate that MUC1-C drives BMI1 transcription by a MYC-dependent mechanism in breast and other cancer cells...
November 28, 2016: Oncogene
https://www.readbyqxmd.com/read/27846863/prognostic-significance-of-mucin-expression-profiles-in-breast-carcinoma-with-signet-ring-cells-a-clinicopathological-study
#6
Ryuji Ohashi, Ayako Hayama, Keiko Yanagihara, Koji Yamashita, Takashi Sakatani, Hiroyuki Takei, Zenya Naito
BACKGROUND: Signet ring cells (SRCs) often accompany gastrointestinal carcinoma, referred to as SRC carcinoma; however, breast cancers containing SRCs have not been well characterized, leaving the prognostic significance of SRCs undetermined. We have described clinicopathological characteristics of patients with breast cancer containing SRCs in relation to the expression levels of MUC1, MUC2, MUC4, MUC5AC, and MUC6. METHODS: Twenty-two breast cancer cases with variable degrees of SRC population were retrospectively studied...
November 15, 2016: Diagnostic Pathology
https://www.readbyqxmd.com/read/27832451/expression-data-analysis-for-the-identification-of-potential-biomarker-of-pregnancy-associated-breast-cancer
#7
Raja Rajeswary Thanmalagan, Leimarembi Devi Naorem, Amouda Venkatesan
Breast cancer affects every 1 of 3000 pregnant women or in the first post-partum year is referred as Pregnancy Associated Breast Cancer (PABC) in mid 30s. Even-though rare disease, classified under hormone receptor negative status which metastasis quickly to other parts by extra cellular matrix degradation. Hence it is important to find an optimal treatment option for a PABC patient. Also additional care should be taken to choose the drug; in order to avoid fetal malformation and post-partum stage side-effects...
November 10, 2016: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/27809866/evidence-of-two-distinct-functionally-specialized-fibroblast-lineages-in-breast-stroma
#8
Mikkel Morsing, Marie Christine Klitgaard, Abbas Jafari, René Villadsen, Moustapha Kassem, Ole William Petersen, Lone Rønnov-Jessen
BACKGROUND: The terminal duct lobular unit (TDLU) is the most dynamic structure in the human breast and the putative site of origin of human breast cancer. Although stromal cells contribute to a specialized microenvironment in many organs, this component remains largely understudied in the human breast. We here demonstrate the impact on epithelium of two lineages of breast stromal fibroblasts, one of which accumulates in the TDLU while the other resides outside the TDLU in the interlobular stroma...
November 3, 2016: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/27802205/the-role-of-molecular-biomarkers-for-predicting-adjacent-breast-cancer-of-atypical-ductal-hyperplasia-diagnosed-on-core-biopsy
#9
Ayfer Kamali Polat, Atilla Soran, Amal Kanbour-Shakir, Ebru Menekse, Fatih Levent Balci, Ronald Johnson
BACKGROUND: Atypical Ductal Hyperplasia (ADH) is a disease of the proliferative breast lesion characterized with atypia and when diagnosed on core needle biopsy (CNB), excisional biopsy is the current management to exclude adjacent cancer, which may found 10 to 20%. OBJECTIVE: The purpose of the study is to investigate the role of biomarkers on surgical decision after the diagnosis of ADH on CNB. METHODS: Patients with pure ADH on core biopsy were retrospectively selected, and categorized according to final pathology after excision into three groups: Group I (n: 39) ADH; Group II (n: 27) ductal carcinoma in situ (DCIS), and Group III (n: 9) invasive cancer (IC)...
September 26, 2016: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/27787640/peripheral-t-cell-responses-to-tumour-antigens-are-associated-with-molecular-immunogenetic-and-cellular-features-of-breast-cancer-patients
#10
Nicole Janssen, Sotirios P Fortis, Lisa Speigl, Christoforos Haritos, Nectaria N Sotiriadou, Michael Sofopoulos, Niki Arnogiannaki, Catherine Stavropoulos-Giokas, Amalia Dinou, Sonia Perez, Graham Pawelec, Constantin N Baxevanis, Christopher Shipp
PURPOSE: Breast cancer is a leading cause of cancer deaths in women, but despite steady improvements in therapies, treatment is still suboptimal. Immunotherapy holds promise as a more effective therapy for breast cancer; supporting this, our prior study showed that patients possessing HER2-reactive CD8+ T cells in blood experience survival superior to patients without these cells. Here, we define a composite set of biomarkers that identify patients with T cell responses to tumour antigens...
January 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27782376/synergistic-anticancer-effect-of-peptide-docetaxel-nanoassembly-targeted-to-tubulin-toward-development-of-dual-warhead-containing-nanomedicine
#11
Saswat Mohapatra, Abhijit Saha, Prasenjit Mondal, Batakrishna Jana, Subhajit Ghosh, Atanu Biswas, Surajit Ghosh
Microtubule dynamics play a crucial role in cancer cell division. Various drugs are developed to target microtubule. Although a few of them show potential in treatment of cancer, but success rate is limited due to their poor bioavailability and lack of specificity. Thus, development of highly bioavailable and target specific anticancer drug is extremely necessary. To address these key issues, here, a combination of approaches such as development of a dodecapeptide-docetaxel nanoassembly targeted to tubulin and MUC1 (mucin 1, cell surface associated glycoprotein) targeting oligonucleotide aptamer conjugated liposome for delivering peptide-docetaxel nanoassembly into the breast cancer cell have been demonstrated...
October 26, 2016: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/27768738/muc1-arf-a-novel-muc1-protein-that-resides-in-the-nucleus-and-is-expressed-by-alternate-reading-frame-translation-of-muc1-mrna
#12
Michael Chalick, Oded Jacobi, Edward Pichinuk, Christian Garbar, Armand Bensussan, Alan Meeker, Ravit Ziv, Tania Zehavi, Nechama I Smorodinsky, John Hilkens, Franz-Georg Hanisch, Daniel B Rubinstein, Daniel H Wreschner
Translation of mRNA in alternate reading frames (ARF) is a naturally occurring process heretofore underappreciated as a generator of protein diversity. The MUC1 gene encodes MUC1-TM, a signal-transducing trans-membrane protein highly expressed in human malignancies. Here we show that an AUG codon downstream to the MUC1-TM initiation codon initiates an alternate reading frame thereby generating a novel protein, MUC1-ARF. MUC1-ARF, like its MUC1-TM 'parent' protein, contains a tandem repeat (VNTR) domain. However, the amino acid sequence of the MUC1-ARF tandem repeat as well as N- and C- sequences flanking it differ entirely from those of MUC1-TM...
2016: PloS One
https://www.readbyqxmd.com/read/27658423/muc1-c-represses-the-crumbs-complex-polarity-factor-crb3-and-downregulates-the-hippo-pathway
#13
Maroof Alam, Audrey Bouillez, Ashujit Tagde, Rehan Ahmad, Hasan Rajabi, Takahiro Maeda, Masayuki Hiraki, Yozo Suzuki, Donald Kufe
Apical-basal polarity and epithelial integrity are maintained in part by the Crumbs (CRB) complex. The C--terminal subunit of MUC1 (MUC1-C) is a transmembrane protein that is expressed at the apical border of normal epithelial cells and aberrantly at high levels over the entire surface of their transformed counterparts. However, it is not known whether MUC1-C contributes to this loss of polarity that is characteristic of carcinoma cells. Here it is demonstrated that MUC1-C downregulates expression of the Crumbs complex CRB3 protein in triple-negative breast cancer (TNBC) cells...
December 2016: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/27633889/harnessing-bioinformatics-for-designing-a-novel-multiepitope-peptide-vaccine-against-breast-cancer
#14
Shirin Mahmoodi, Navid Nezafat, Abolfazl Barzegar, Manica Negahdaripour, Ali R Nikanfar, Nosratollah Zarghami, Younes Ghasemi
Breast cancer (BC) remains as one of the important causes of cancer deaths among women globally. Therefore, finding an effective treatment for BC is really needed. Cancer immunotherapy, as an emerging field, has a notable role in BC therapy. Peptide vaccines possess an outstanding role among different strategies in cancer immunotherapy. In vaccine design for cancer, induction of cellular and humoral immune responses should be considered. In the current study, cytolytic T lymphocytes (CTL) epitopes were evoked from human epidermal growth factor receptor (HER2), mucin 1 protein (MUC1), and heparanase antigenic proteins; and helper T lymphocytes (HTL) epitopes were determined from survivin protein by various immunoinformatics servers...
2016: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/27630326/association-of-ca27-29-and-circulating-tumor-cells-before-and-at-different-times-after-adjuvant-chemotherapy-in-patients-with-early-stage-breast-cancer-the-success-trial
#15
RANDOMIZED CONTROLLED TRIAL
Philip Hepp, Ulrich Andergassen, Bernadette Jäger, Elisabeth Trapp, Marianna Alunni-Fabbroni, Thomas W P Friedl, Nadeschda Hecker, Ralf Lorenz, Peter Fasching, Andreas Schneeweiss, Tanja Fehm, Wolfgang Janni, Brigitte Rack
BACKGROUND: Evidence for the prognostic value of circulating tumor cells (CTCs) in early-stage breast cancer is swiftly increasing. An alternative approach for identifying patients at risk for recurrence is based on the detection of the mucin-1 (MUC1)-based tumor marker CA27.29. Here we report the association of these two prognostic markers before and immediately after chemotherapy (CHT), as well as after 2 and 5 years of follow-up. PATIENTS AND METHODS: The SUCCESS trial compared fluorouracil, epirubicin and cyclophosphamide followed by docetaxel vs...
2016: Anticancer Research
https://www.readbyqxmd.com/read/27567952/antibody-guided-in-vivo-imaging-for-early-detection-of-mammary-gland-tumors
#16
Laura Jeffords Moore, Lopamudra Das Roy, Ru Zhou, Priyanka Grover, Shu-Ta Wu, Jennifer M Curry, Lloye M Dillon, Priya M Puri, Mahboubeh Yazdanifar, Rahul Puri, Pinku Mukherjee, Didier Dréau
BACKGROUND: Earlier detection of transformed cells using target-specific imaging techniques holds great promise. We have developed TAB 004, a monoclonal antibody highly specific to a protein sequence accessible in the tumor form of MUC1 (tMUC1). We present data assessing both the specificity and sensitivity of TAB 004 in vitro and in genetically engineered mice in vivo. METHODS: Polyoma Middle T Antigen mice were crossed to the human MUC1.Tg mice to generate MMT mice...
August 2016: Translational Oncology
https://www.readbyqxmd.com/read/27367740/aberrant-glycosylation-of-anchor-optimized-muc1-peptides-can-enhance-antigen-binding-affinity-and-reverse-tolerance-to-cytotoxic-t-lymphocytes
#17
Latha B Pathangey, Vani Lakshminarayanan, Vera J Suman, Barbara A Pockaj, Pinku Mukherjee, Sandra J Gendler
Cancer vaccines have often failed to live up to their promise, although recent results with checkpoint inhibitors are reviving hopes that they will soon fulfill their promise. Although mutation-specific vaccines are under development, there is still high interest in an off-the-shelf vaccine to a ubiquitous antigen, such as MUC1, which is aberrantly expressed on most solid and many hematological tumors, including more than 90% of breast carcinomas. Clinical trials for MUC1 have shown variable success, likely because of immunological tolerance to a self-antigen and to poor immunogenicity of tandem repeat peptides...
June 29, 2016: Biomolecules
https://www.readbyqxmd.com/read/27272845/expression-of-the-tumor-associated-mucin-1-epitope-analyzed-with-the-humanized-pankomab-gex%C3%A2-antibody-in-malignant-and-normal-tissues-of-the-head-and-neck
#18
Irmi Wiest, Christoph Alexiou, Klaus Friese, Peter Betz, Jutta Tübel, Steffen Goletz, Darius Dian, Udo Jeschke
BACKGROUND: During neoplasia, glycosylation changes. In this setting, mucins, especially mucin 1 (MUC1), become carriers for oncofetal carbohydrates and relieve invasive growth. The recently described tumor-associated MUC1 epitope TA-MUC1 is primarily restricted to malignancies and is overexpressed in these tissues. The humanized monoclonal antibody PankoMab-GEX specifically recognizes TA-MUC1. MATERIALS AND METHODS: Laryngeal cancer specimens (n=125) and normal tissue of head and neck (n=7) were used in this study...
June 2016: Anticancer Research
https://www.readbyqxmd.com/read/27221150/regulation-of-mucin-1-and-multidrug-resistance-protein-1-by-honokiol-enhances-the-efficacy-of-doxorubicin-mediated-growth-suppression-in-mammary-carcinoma-cells
#19
Padmamalini Thulasiraman, Andrea Butts Johnson
Understanding the link between chemoresistance and cancer progression may identify future targeted therapy for breast cancer. One of the mechanisms by which chemoresistance is attained in cancer cells is mediated through the expression of multidrug resistance proteins (MRPs). Acquiring drug resistance has been correlated to the emergence of metastasis, accounting for the progression of the disease. One of the diagnostic markers of metastatic progression is the overexpression of a transmembrane protein called Mucin 1 (MUC1) which has been implicated in reduced survival rate...
August 2016: International Journal of Oncology
https://www.readbyqxmd.com/read/27217294/muc1-c-stabilizes-mcl-1-in-the-oxidative-stress-response-of-triple-negative-breast-cancer-cells-to-bcl-2-inhibitors
#20
Masayuki Hiraki, Yozo Suzuki, Maroof Alam, Kunihiko Hinohara, Masanori Hasegawa, Caining Jin, Surender Kharbanda, Donald Kufe
Aberrant expression of myeloid cell leukemia-1 (MCL-1) is a major cause of drug resistance in triple-negative breast cancer (TNBC) cells. Mucin 1 (MUC1) is a heterodimeric oncoprotein that is aberrantly overexpressed in most TNBC. The present studies show that targeting the oncogenic MUC1 C-terminal subunit (MUC1-C) in TNBC cells with silencing or pharmacologic inhibition with GO-203 is associated with downregulation of MCL-1 levels. Targeting MUC1-C suppresses the MEK → ERK and PI3K → AKT pathways, and in turn destabilizes MCL-1...
2016: Scientific Reports
keyword
keyword
70008
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"